KSB Tugen

KSB Tugen is a biotechnology company focused on the development of next-generation T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors. The company leverages a proprietary platform to identify and validate novel cancer-testis antigens and develop high-affinity TCRs that can effectively target and eliminate malignant cells. KSB Tugen aims to overcome the limitations of current cell therapies in solid tumor environments by enhancing T-cell infiltration and persistence. Their pipeline includes several pre-clinical programs targeting various high-prevalence cancers with significant unmet medical needs.